In Silico药物发现市场报告：2030 年趋势、预测与竞争分析

In Silico药物发现的趋势和预测

到 2030 年，全球In Silico药物发现市场预计将达到 55 亿美元，2024 年至 2030 年复合年增长率为 10.2%。该市场的主要驱动力是越来越多地关注减少用药错误、在药物发现中越来越多地采用云端基础的应用程式以及计算生物学的持续进步。全球In Silico药物发现市场的未来前景广阔，委外研发机构、製药业和学术/研究机构市场都有机会。

• Lucintel 预测，由于在药物发现过程中越来越多地采用虚拟筛检和目标发现，软体即服务 (SaaS) 将在预测期内实现最高成长。
• 製药业仍将是该市场的最大部分，因为In Silico药物发现有助于製药公司减少开发新药的时间和成本。
• 由于生物製药公司研发支出增加、市场参与企业的存在以及大量患有各种慢性病和感染疾病的患者，预计北美在预测期内仍将是最大的地区。

In Silico药物发现市场的新趋势

In Silico药物发现市场出现了一些新兴趋势，标誌着药物开发和研究的面貌正在改变。

• 人工智慧和机器学习的融合：人工智慧和机器学习越来越多地融入药物开发过程中，进一步提高药物设计的预测准确性和优化。这些技术用于分析大型资料集并更准确地预测药物交互作用的性质。
• 个人化医疗：由于基因组学和生物资讯学的进步，对个人化医疗的兴趣与日俱增。In Silico模型可以提高疗效，同时最大限度地减少副作用。
• 云端基础的平台：云端基础的平台由于能够提供可扩展的In Silico药物发现解决方案而受到越来越多的关注。此类平台可实现协作、资料共用和计算分析，以进一步简化药物发现。
• 高效能运算：高效能运算的应用正在迅速扩展，能够实现复杂的模拟和大规模资料分析。这些使得In Silico建模更加详细和准确，从而加速药物发现和开发。
• 多体学资料的整合：多组体学资料（例如基因组学、蛋白质组学和代谢体学）的整合是In Silico药物发现中快速发展的部分。这些趋势使人们能够更深入地了解生物系统并增强潜在药物标靶的识别。

这将进一步提高药物发现过程的技术能力、精确度和效率，并将继续改变In Silico药物发现市场的面貌。

In Silico药物发现市场的最新趋势

In Silico药物发现市场的最新趋势描绘了重大进步和创新的景象。这些因素导致了药物发现方法的显着增长。

• 人工智慧演算法的开发：正在开发新的演算法来改进预测建模和虚拟筛检，例如人工智慧机器学习演算法的开发。这提高了识别候选药物的速度和准确性，并加速了药物发现的过程。
• 基因组资料整合：基因组资料整合将为药物标靶识别和个人化医疗方法带来更精确的In Silico模型。这一趋势将有助于开发依赖遗传资讯的治疗方法。
• 基于云端基础的解决方案的增加：云端基础的解决方案如今非常普遍，为In Silico药物发现提供了可扩展且灵活的平台。这些解决方案透过资料共用实现研究人员和製药公司之间的协作。
• 改进的高效能运算：改进的高效能运算技术可以实现复杂的模拟和资料分析，支援详细的In Silico建模，并加快药物发现过程。
• 开发多组体学整合工具：整合多体学资料的方法正在迅速发展，提供生物系统的全面视图。这些进展将提高我们识别药物标靶和开发有效治疗方法的能力。

这些因素透过提高技术能力、增加应用并最终加速药物发现过程来影响In Silico药物发现市场。

In Silico药物发现市场的策略性成长机会

In Silico药物发现市场列出了主要应用的各种策略成长机会。正确识别和利用机会将促进该市场的进一步扩张和创新。

• 人工智慧主导的药物发现：人工智慧驱动平台的开发将增加预测建模和虚拟筛检。这一事实使得药物发现更加高效并降低了开发成本。
• 个人化医疗解决方案：我们看到个人化医疗In Silico模型的开发不断增长。透过在个体基因层面上定製药物发现，公司可以创造出具有更高功效的治疗方法。
• 云端基础的药物发现平台：云端基础的平台的成长提供了提供可扩展且可存取的药物发现解决方案的机会。这些平台支援世界各地研究团队之间的协作和资料共用。
• 高效能运算服务：高效能运算服务可以满足药物发现中的复杂模拟和大规模资料分析需求。帮助进行大规模In Silico建模以加速药物开发。
• 多组体学整合技术：整合多组体学资料和技术的投资创造了为药物标靶识别和开发过程增加附加价值的机会。这种方法可以更深入地了解生物系统，并显着改善药物发现结果。

这些新机会将透过持续的技术开发、扩大的服务范围和促进药物发现的创新方法来巩固In Silico药物发现市场的成长。

In Silico药物发现市场推广因素与挑战

In Silico药物发现市场不断受到技术、经济和监管方面的影响。此外，我们将说明市场驱动因素/挑战以及如何克服它们。

推动In Silico药物发现市场的因素包括：

1. 技术进步：技术进步：人工智慧、机器学习和高效能运算的创新是In Silico药物发现成长的强大驱动力。这些技术提高了预测准确性并简化了药物发现过程。

2.研发投入增加：研发投入增加是推动In Silico药物发现领域成长率的因素之一。这项投资将支持新工具和技术的开发，以提高药物发现的效率。

3. 对个人化医疗的需求：个人化医疗的概念推动了对In Silico模型的需求，该模型根据个人的基因组成来个性化药物发现。这可以实现更好的治疗，同时减少副作用。

4. 云端采用：云端运算的普及为药物发现提供了可扩展且敏捷的平台。云端基础的解决方案促进协作、资料共用和运算分析。

5. 多组体学资料的整合：这种整合使得基于对生物系统的整体理解In Silico药物发现成为可能。这一趋势将导致更准确的药物标靶识别和开发。

In Silico药物发现市场面临的挑战如下。

1.资料隐私和安全：In Silico药物发现的关键挑战之一是确保所使用的敏感资料的隐私和安全。保护智慧财产权和患者资料对于建立信任和确保合规性至关重要。

2. 整合复杂性：无论如何，整合各种资料来源和技术来建立In Silico模型是一个非常复杂的挑战。出现了相容性问题，需要持续整合到无缝资料流。

3. 先进技术的高成本：组织经常发现与先进技术和计算资源相关的巨大成本是一个主要障碍。这是In Silico药物发现的成本和效益之间的平衡。

这些驱动因素/挑战推动了In Silico药物发现市场，并透过影响成长、创新和整体市场动态的因素来塑造市场。

In Silico药物发现（按细分市场）

该研究包括按类型、标靶治疗领域、工作流程、最终用途和地区对全球In Silico药物发现的预测。

In Silico药物发现市场的国家前景

由于人工智慧、机器学习和巨量资料分析的集成，In Silico药物发现已成为发展最快的领域之一。这些正在改变药物发现过程，以提高预测准确性并减少时间和成本。主要发展：美国、中国、德国、印度和日本反映了这些国际趋势，因为他们看到了该领域投资和创新的增加。

• 美国：人工智慧和机器学习在美国正在取得长足进步。其结果是药物发现领域的预测建模和虚拟筛检有了显着改善。先进的演算法、关于困境和生物目标的巨量资料以及其他因素越来越多地被公司用来更准确、更快速地识别潜在的候选药物，从而加速药物开发，成为一种快速且经济的方法。
• 中国：中国也致力于整合人工智慧和生物资讯学以加速药物发现。最近的发展推动了预测药物交互作用和功效的先进计算工具的开发，这是中国实现成为世界製药创新领导者的梦想的一步。
• 德国：德国在将高效能运算应用于药物发现过程方面正在取得进展。德国依靠其卓越的研发基础设施来开发新的In Silico模型，以改善药物发现目标识别和药物设计优化的过程。
• 印度：建立国家药物开发和研究能力，重点是使In Silico药物发现工具的获取民主化、转向云端基础的平台以及与全球公司的伙伴关係。
• 日本：日本正在透过整合基因组学和人工智慧来加强In Silico药物发现平台。日本目前的重点是利用此类技术进行精准医疗并加速标靶治疗。

常问问题

Q1.市场规模有多大？

答：到 2030 年，全球In Silico药物发现市场预计将达到 55 亿美元。

Q2.市场成长预测如何？

答：2024 年至 2030 年，全球In Silico药物发现市场预计将以 10.2% 的复合年增长率成长。

Q3.影响市场成长的关键驱动因素有哪些？

答：这个市场的主要驱动力是人们越来越关注减少用药错误、在药物发现中越来越多地采用云端基础的应用程式以及计算生物学的持续进步。

Q4.市场的主要细分市场有哪些？

答：In Silico药物发现市场的未来前景广阔，为受託研究机构、製药业和学术/研究机构市场提供了机会。

Q5. 市场上主要企业有哪些？

答：主要的In Silico药物发现公司有：

• Curia
• Certara
• Charles River Laboratories
• Chemical Computing
• GenScript
• Sygnature Discovery
• Abzena

Q6.未来最大的细分市场是什么？

答：Lucintel 预测，由于药物发现过程中越来越多地采用虚拟筛检和目标发现，软体即服务 (SaaS) 将在预测期内实现最高成长。

Q7. 未来五年预计哪个地区的市场最大？

答：由于生物製药参与企业研发支出增加、市场占有率强劲以及患有各种慢性和感染疾病的患者人数众多，北美在预测期内仍然是最大的地区，这种情况很可能会持续下去。

Q8. 可以客製化报告吗？

答：是的，Lucintel 列出了 10% 的客製化服务，无需额外费用。

目录

第一章执行摘要

第二章全球In Silico药物发现市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球In Silico药物发现市场趋势（2018-2023）和预测（2024-2030）
• 按类型分類的全球In Silico药物发现市场
  • SaaS（Software-as-a-Service）
  • CaaS（Consulting-as-a-Service）
  • 软体
• 按目标治疗领域分類的全球In Silico药物发现市场
  • 人类免疫力缺乏病毒（HIV）
  • 感染疾病
  • 代谢紊乱
  • 精神障碍
  • 肌肉骨骼疾病
  • 神经系统疾病
  • 肿瘤性疾病
  • 呼吸系统疾病
  • 其他的
• 按工作流程分類的全球In Silico药物发现市场
  • 发现
  • 物体辨识
  • 反向对接
  • 生物资讯学
  • 蛋白质结构预测
  • 目标检验
  • 候选人发现
  • 药效基团
  • 其他的
• 按最终用途分類的全球In Silico药物发现市场
  • 委託研究组织
  • 製药业
  • 学术研究所
  • 其他的

第四章 2018-2030年区域市场趋势及预测分析

• 按地区分類的全球In Silico发现市场
• 北美In Silico药物发现市场
• 欧洲In Silico药物发现市场
• 亚太地区In Silico药物发现市场
• 其他地区的In Silico药物发现市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球In Silico药物发现市场成长机会（按类型）
  • 按目标治疗领域分類的全球In Silico药物发现市场的成长机会
  • 按工作流程分類的全球In Silico药物发现市场成长机会
  • 全球In Silico药物发现市场成长机会（按最终用途）
  • 全球In Silico药物发现市场成长机会（按地区）
• 全球In Silico药物发现市场的新趋势
• 战略分析
  • 新产品开发
  • 扩大全球In Silico药物发现市场的能力
  • 全球In Silico药物发现市场的合併、收购和合资企业
  • 认证和许可

第七章主要企业概况

• Curia
• Certara
• Charles River Laboratories
• Chemical Computing
• GenScript
• Sygnature Discovery
• Abzena

In-Silico Drug Discovery Trends and Forecast

The future of the global in-silico drug discovery market looks promising with opportunities in the contract research organizations, pharmaceutical industry, and academic & research institutes markets. The global in-silico drug discovery market is expected to reach an estimated $5.5 billion by 2030 with a CAGR of 10.2% from 2024 to 2030. The major drivers for this market are rising focus towards reduction of medication errors, increasing adoption of cloud-based applications in drug discovery, and on-going advancements in computational biology.

• Lucintel forecasts that software as a service is expected to witness the highest growth over the forecast period due to its increasing adoption for virtual screening and target fising in the drug discovery procedure.
• Within this market, pharmaceutical industry will remain the largest segment due as in-silico drug discovery helps the pharmaceutical companies to reduce the time and cost of developing new drugs.
• North America will remain the largest region over the forecast period due to increasing R&D expenditure by biopharma company, strong presence of market players, and large patient population suffering from various chronic and infectious diseases in the region.

Emerging Trends in the In-Silico Drug Discovery Market

There are several emerging trends in the In-Silico Drug Discovery market, which mark the changing face of the drug development and research landscape.

• AI and Machine Learning Integration: Artificial intelligence and machine learning have started to be integrated more and more into drug development processes, further enhancing predictive accuracy and optimization of drug design. These technologies have been used to analyze large datasets and predict the nature of drug interactions more accurately.
• Personalized Medicine: Interest in personalized medicine is driven by advances in genomics and bioinformatics. In-silico models for tailoring drug discovery and development to individual genetic profiles can enhance efficacy while minimizing adverse effects.
• Cloud-Based Platforms: Cloud-based platforms are of increasing interest due to their scalable delivery of in-silico drug discovery solutions. Such platforms enable collaboration, data sharing, and computational analysis that further streamline drug discovery.
• High-Performance Computing: The application of high-performance computing is growing fast, which allows for complex simulations and large-scale data analysis. These will enable more detailed and correct in-silico modeling, accelerating drug discovery and development.
• Integration of Multi-Omics Data: Integration of multi-omics data, such as genomics, proteomics, and metabolomics, is a rapidly developing area in in-silico drug discovery. These trends allow for a more in-depth understanding of biological systems and enhance the identification of potential drug targets.

This will continue to reshape the face of the In-Silico Drug Discovery market by further developing the technological capabilities, precision, and efficiency of drug discovery processes.

Recent Developments in the In-Silico Drug Discovery Market

Recent developments in the In-Silico Drug Discovery market have painted a picture of great advancement and innovation. These are the factors that contribute to significant growth in methodology for drug discovery.

• AI Algorithm Development: New algorithms, such as developing machine learning algorithms for AI, are being developed to improve predictive modeling and virtual screening. This increases the rate and accuracy of identification of drug candidates and accelerates the processes involved in drug discovery.
• Integration of Genomic Data: The integration of genomic data moves on to more precise in-silico models for identification of drug targets and personalized medicine approaches. This trend contributes to the development of therapies depending on genetic information.
• Increase in Cloud-Based Solutions: Cloud-based solutions are very common today, offering scalable and flexible platforms for in-silico drug discovery. These solutions enable the collaboration of researchers and pharmaceutical companies through data sharing.
• Improvement of high-performance computing: Improvement in high-performance computing technologies can allow complex simulations and data analysis, thus supporting detailed in-silico modeling and speeding up drug development processes.
• Development of Tools for Multi-Omics Integration: Approaches toward integrating multi-omics data are rapidly improving, providing comprehensive views into biological systems. Such development enhances the capability for the identification of drug targets and development of effective therapies.

These factors influence the In-Silico Drug Discovery market by improving technological capabilities, increasing applications, and thus accelerating the process for drug discovery.

Strategic Growth Opportunities for In-Silico Drug Discovery Market

The In-Silico Drug Discovery market presents various strategic growth opportunities from major applications. Proper identification of opportunities and building on them would facilitate further expansion and innovations in this market.

• AI-driven drug discovery: The development of AI-driven platforms will increase predictive modeling and virtual screening. Due to that fact, drug discovery becomes more efficient while development costs decrease.
• Personalized Medicine Solutions: Growth is seen in the development of in-silico models for personalized medicine. Companies can create therapies with much higher effectiveness by tailoring drug discovery at an individual genetic level.
• Cloud-Based Drug Discovery Platforms: The growth of cloud-based platforms presents an opportunity to provide scalable and accessible drug discovery solutions. These platforms support collaboration and data sharing among global research teams.
• High-Performance Computing Services: The requirement for complex simulations and large-scale data analysis in drug discovery can be addressed by leveraging high-performance computing services. It helps perform extensive in-silico modeling and accelerates the development of drugs.
• Multi-omics Integration Technologies: Investments in integrated multi-omics data technologies create opportunities that can bring more value to the process of drug target identification and development. This approach provides a much deeper understanding of biological systems, which will significantly improve the outcomes related to drug discovery.

These emerging opportunities consolidate growth in the In-Silico Drug Discovery market through continued technological development, expanded service offerings, and the furtherance of innovative approaches toward drug development.

In-Silico Drug Discovery Market Driver and Challenges

It is constantly shaped by the facets of technology, economics, and regulation. Further, it describes drivers and challenges associated with the market and how to overcome them.

The factors responsible for driving the in-silico drug discovery market include:

1. Technological advancements: Innovation in AI, machine learning, and high-performance computing-a strong driver of growth in in-silico drug discovery. These technologies enhance predictive accuracy and streamline the process of drug discovery.

2. Increasing R&D Investment: Growing investment in research and development is one of the factors increasing the growth rate in the field of in-silico drug discovery. This investment supports new tool and technology development, hence enhancing efficiency in drug discovery.

3. Demand for Personalized Medicine: The concept of personalized medicine promotes the demand for in-silico models that individualize drug discovery concerning the person's genetic makeup. This offers better treatment with reduced side effects.

4. Cloud Adoption: With widening adoption, cloud computing enables access to scalable and agile platforms for drug discovery. Cloud-based solutions facilitate collaboration, data sharing, and computation analyses.

5. Integration of Multi-omics Data: Such integration thereby allows in-silico drug discovery with a holistic understanding of biological systems. This trend brings better identification and development of drug targets more accurately.

Challenges in the in-silico drug discovery market are:

1. Data Privacy and Security: One of the key challenges with in-silico drug discovery is ensuring privacy and security regarding sensitive data used. The protection of intellectual property and patient data is of utmost importance for building trust and ensuring compliance.

2. Complexity of Integration: In any case, a variety of data sources and technologies being integrated into cohesive in-silico models pose a very complex challenge. Compatibility issues are raised and need to be integrated into a seamless flow of data continuously.

3. High Costs of Advanced Technologies: Organizations often find that huge expenses related to advanced technologies and computational resources are a big obstacle. This balances out with the cost relative to the benefits derived in in-silico drug discovery.

These drivers and challenges are driving the In-Silico Drug Discovery market, shaping it with factors that influence growth, innovation, and overall market dynamics.

List of In-Silico Drug Discovery Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies in-silico drug discovery companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the in-silico drug discovery companies profiled in this report include-

• Curia
• Certara
• Charles River Laboratories
• Chemical Computing
• GenScript
• Sygnature Discovery
• Abzena

In-Silico Drug Discovery by Segment

The study includes a forecast for the global in-silico drug discovery by type, target therapeutic area, workflow, end use, and region.

In-Silico Drug Discovery Market by Type [Analysis by Value from 2018 to 2030]:

• Software as a service
• Consultancy as a service
• Software

In-Silico Drug Discovery Market by Target Therapeutic Area [Analysis by Value from 2018 to 2030]:

• Human Immunodeficiency Virus (HIV)
• Infectious diseases
• Metabolic disorders
• Mental disorders
• Musculoskeletal disorders
• Neurological disorders
• Oncological disorders
• Respiratory disorders
• Others

In-Silico Drug Discovery Market by Workflow [Analysis by Value from 2018 to 2030]:

• Discovery
• Target identification
• Reverse docking
• Bioinformatics
• Protein structure prediction
• Target validation
• Lead discovery
• Pharmacophore
• Others

In-Silico Drug Discovery Market by End Use [Analysis by Value from 2018 to 2030]:

• Contract research organizations
• Pharmaceutical industry
• Academic & research institutes
• Others

In-Silico Drug Discovery Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the In-Silico Drug Discovery Market

In-silico drug discovery has become one of the fast-emerging fields with the integration of AI, machine learning, and big data analytics. These are transforming the processes of drug discovery to increase predictive accuracy and reduce time and cost. Key Developments: United States, China, Germany, India, and Japan reflect these international trends as increased investments and technological innovations have been observed in the area.

• United States: In the US, big strides are being taken in AI and machine learning. Due to that, predictive modeling and virtual screening within the realm of drug search have gotten tremendous improvements. Advanced algorithms, big data on plight and target biology, and other factors have increasingly been employed by firms to identify potential drug candidates more correctly and fast, hence promoting quicker and affordable ways of developing drugs.
• China: China also emphasizes integrating AI with bioinformatics for accelerated drug discovery. Recent years have seen the development of sophisticated computational tools that predict drug interaction and efficacy, a step toward attaining the country's dream of becoming a global leader in pharmaceutical innovation.
• Germany: High-performance computing is increasingly applied to the process of drug discovery in Germany. It bases its hopes on good R&D infrastructure for the development of new in-silico models that help to improve drug target identification and optimization processes in drug design.
• India: India is focused on the democratization of access to in-silico drug discovery tools, a trend towards cloud-based platforms, and partnerships with global firms to build its national capabilities around drug development and research.
• Japan: Japan is enhancing its in-silico drug development platform by incorporating genomics and AI. The immediate focus of the country is to use such technologies for precision medicine and acceleration of targeted therapies.

Features of the Global In-Silico Drug Discovery Market

Market Size Estimates: In-silico drug discovery market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: In-silico drug discovery market size by various segments, such as by type, target therapeutic area, workflow, end use, and region in terms of value ($B).

Regional Analysis: In-silico drug discovery market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, target therapeutic areas, workflow, end uses, and regions for the in-silico drug discovery market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the in-silico drug discovery market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q1. What is the in-silico drug discovery market size?

Answer: The global in-silico drug discovery market is expected to reach an estimated $5.5 billion by 2030.

Q2. What is the growth forecast for in-silico drug discovery market?

Answer: The global in-silico drug discovery market is expected to grow with a CAGR of 10.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the in-silico drug discovery market?

Answer: The major drivers for this market are rising focus towards reduction of medication errors, increasing adoption of cloud-based applications in drug discovery, and on-going advancements in computational biology.

Q4. What are the major segments for in-silico drug discovery market?

Answer: The future of the in-silico drug discovery market looks promising with opportunities in the contract research organizations, pharmaceutical industry, and academic & research institutes markets.

Q5. Who are the key in-silico drug discovery market companies?

Answer: Some of the key in-silico drug discovery companies are as follows:

• Curia
• Certara
• Charles River Laboratories
• Chemical Computing
• GenScript
• Sygnature Discovery
• Abzena

Q6. Which in-silico drug discovery market segment will be the largest in future?

Answer: Lucintel forecasts that software as a service is expected to witness the highest growth over the forecast period due to its increasing adoption for virtual screening and target fising in the drug discovery procedure.

Q7. In in-silico drug discovery market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing R&D expenditure by biopharma company, strong presence of market players, and large patient population suffering from various chronic and infectious diseases in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the in-silico drug discovery market by type (software as a service, consultancy as a service, and software), target therapeutic area (human immunodeficiency virus (HIV), infectious diseases, metabolic disorders, mental disorders, musculoskeletal disorders, neurological disorders, oncological disorders, respiratory disorders, and others), workflow (discovery, target identification, reverse docking, bioinformatics, protein structure prediction, target validation, lead discovery, pharmacophore, and others), end use (contract research organizations, pharmaceutical industry, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global In-Silico Drug Discovery Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global In-Silico Drug Discovery Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global In-Silico Drug Discovery Market by Type
  • 3.3.1: Software as a service
  • 3.3.2: Consultancy as a service
  • 3.3.3: Software
• 3.4: Global In-Silico Drug Discovery Market by Target Therapeutic Area
  • 3.4.1: Human Immunodeficiency Virus (HIV)
  • 3.4.2: Infectious diseases
  • 3.4.3: Metabolic disorders
  • 3.4.4: Mental disorders
  • 3.4.5: Musculoskeletal disorders
  • 3.4.6: Neurological disorders
  • 3.4.7: Oncological disorders
  • 3.4.8: Respiratory disorders
  • 3.4.9: Others
• 3.5: Global In-Silico Drug Discovery Market by Workflow
  • 3.5.1: Discovery
  • 3.5.2: Target identification
  • 3.5.3: Reverse docking
  • 3.5.4: Bioinformatics
  • 3.5.5: Protein structure prediction
  • 3.5.6: Target validation
  • 3.5.7: Lead discovery
  • 3.5.8: Pharmacophore
  • 3.5.9: Others
• 3.6: Global In-Silico Drug Discovery Market by End Use
  • 3.6.1: Contract research organizations
  • 3.6.2: Pharmaceutical industry
  • 3.6.3: Academic & research institutes
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global In-Silico Drug Discovery Market by Region
• 4.2: North American In-Silico Drug Discovery Market
  • 4.2.1: North American In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.2.2: North American In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others
• 4.3: European In-Silico Drug Discovery Market
  • 4.3.1: European In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.3.2: European In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others
• 4.4: APAC In-Silico Drug Discovery Market
  • 4.4.1: APAC In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.4.2: APAC In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others
• 4.5: ROW In-Silico Drug Discovery Market
  • 4.5.1: ROW In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.5.2: ROW In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global In-Silico Drug Discovery Market by Type
  • 6.1.2: Growth Opportunities for the Global In-Silico Drug Discovery Market by Target Therapeutic Area
  • 6.1.3: Growth Opportunities for the Global In-Silico Drug Discovery Market by Workflow
  • 6.1.4: Growth Opportunities for the Global In-Silico Drug Discovery Market by End Use
  • 6.1.5: Growth Opportunities for the Global In-Silico Drug Discovery Market by Region
• 6.2: Emerging Trends in the Global In-Silico Drug Discovery Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global In-Silico Drug Discovery Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global In-Silico Drug Discovery Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Curia
• 7.2: Certara
• 7.3: Charles River Laboratories
• 7.4: Chemical Computing
• 7.5: GenScript
• 7.6: Sygnature Discovery
• 7.7: Abzena